Delayed
London S.E.
12:35:15 2020-10-29 pm EDT
|
5-day change
|
1st Jan Change
|
55
GBX
|
+5.77%
|
|
+4.76%
|
-11.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
57.12
|
296.4
|
327.9
|
1,764
|
1,342
|
1,393
|
-
|
-
|
Enterprise Value (EV)
1 |
26.48
|
163.3
|
216.7
|
1,573
|
1,166
|
1,393
|
1,393
|
1,393
|
P/E ratio
|
-1.84
x
|
-3.5
x
|
-7
x
|
-25.1
x
|
-221
x
|
-24.2
x
|
-39.9
x
|
-167
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
10.9
x
|
4,633
x
|
-
|
293
x
|
21.1
x
|
5.65
x
|
EV / Revenue
|
-
|
-
|
10.9
x
|
4,633
x
|
-
|
293
x
|
21.1
x
|
5.65
x
|
EV / EBITDA
|
-1,405,231
x
|
-5,684,746
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,687,082
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
13,173
|
57,899
|
66,021
|
81,634
|
85,951
|
81,082
|
-
|
-
|
Reference price
2 |
5.750
|
7.000
|
6.720
|
26.13
|
19.88
|
22.26
|
22.26
|
22.26
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/3/22
|
3/7/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
29.97
|
0.3807
|
-
|
4.754
|
66.09
|
246.4
|
EBITDA
|
-40.65
|
-52.14
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-41.08
|
-52.71
|
-54.92
|
-62.96
|
-53.4
|
-106.6
|
-87.68
|
51.03
|
Operating Margin
|
-
|
-
|
-183.28%
|
-16,539.32%
|
-
|
-2,242.91%
|
-132.67%
|
20.71%
|
Earnings before Tax (EBT)
1 |
-39.21
|
-46.13
|
-41.64
|
-56.89
|
-42.59
|
-102.5
|
-85.88
|
44.99
|
Net income
1 |
-31.94
|
-46.23
|
-41.63
|
-57.1
|
-42.97
|
-103.8
|
-84.36
|
46.53
|
Net margin
|
-
|
-
|
-138.92%
|
-15,000.24%
|
-
|
-2,182.67%
|
-127.65%
|
18.88%
|
EPS
2 |
-3.133
|
-2.000
|
-0.9600
|
-1.040
|
-0.0900
|
-0.9183
|
-0.5580
|
-0.1333
|
Free Cash Flow
|
-33.86
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/3/22
|
3/7/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.3807
|
-
|
-
|
-
|
-
|
-
|
-
|
1.2
|
3.553
|
7.594
|
12.36
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.33
|
-20.04
|
-16.93
|
-13.08
|
-12.51
|
-17.58
|
-7.845
|
-13.45
|
-15.09
|
-21.73
|
-24.36
|
-29.67
|
-31.16
|
-28.96
|
-27.43
|
Operating Margin
|
-
|
-
|
-
|
-
|
-3,285.81%
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,471.93%
|
-877.06%
|
-381.42%
|
-221.97%
|
Earnings before Tax (EBT)
1 |
-17.61
|
-19.79
|
-14.6
|
-13.48
|
-8.663
|
-13.12
|
-6.689
|
-12.08
|
-11.21
|
-20.01
|
-23.4
|
-28.98
|
-30.17
|
-27.24
|
-26.14
|
Net income
1 |
-17.43
|
-19.86
|
-14.67
|
-13.53
|
-8.687
|
-13.26
|
-6.933
|
-12.11
|
-11.17
|
-20.61
|
-23.62
|
-29.25
|
-30.44
|
-27.44
|
-26.34
|
Net margin
|
-
|
-
|
-
|
-
|
-2,281.88%
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,436.86%
|
-856.57%
|
-361.36%
|
-213.12%
|
EPS
2 |
-0.4000
|
-0.4000
|
-0.3200
|
-0.0300
|
-0.1600
|
-0.2400
|
-0.0800
|
-0.1600
|
-0.0200
|
-0.0400
|
-0.2100
|
-0.2617
|
-0.2650
|
-0.1500
|
-0.1425
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/3/22
|
8/9/22
|
11/9/22
|
3/7/23
|
5/9/23
|
8/3/23
|
11/2/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
30.6
|
133
|
111
|
191
|
177
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-33.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.04
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/3/22
|
3/7/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
22.26
USD Average target price
36.17
USD Spread / Average Target +62.47% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.17% | 126B | | +24.67% | 118B | | +23.64% | 27.87B | | -17.74% | 20.95B | | -16.08% | 16.92B | | -15.21% | 16.18B | | +11.91% | 14.84B | | -47.10% | 14.79B | | +54.50% | 14.08B |
Bio Therapeutic Drugs
|